A Pharmacokinetic Study to Characterize JNJ-39393406 in the Cerebrospinal Fluid of Healthy Volunteers

Phase 1 Completed 12 enrolled Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

RandomizedParallel-groupDouble-blind

Summary

The purpose of this study is to investigate the concentration of JNJ-39393406 achieved in the blood and cerebrospinal fluid of healthy adult volunteers following administration of a single dose of JNJ-39393406.

Timeline

Start: 2010-09
Primary completion: 2010-11
Completion: 2010-11

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	JNJ-39393406	Small molecule	200 mg	Oral

Indications

No indication recorded.